TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02836301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control ending - Uplifting
Description: The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Consequences Ending
Description: A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Consequences Ending
Description: A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unresolved Ending
Description: In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unresolved Ending
Description: In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
Study: NCT03739138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data.
Study: NCT02023437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser cataract surgery
Description: The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual cataract surgery
Description: Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Study: NCT00753532

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 200mg of Palm vitamin E (tocotrienols) or placebo
Description: Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 200mg of Palm vitamin E (tocotrienols) or placebo
Description: Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
Study: NCT04623944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKX101 - CAR NK cell therapy
Description: NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
Study: NCT00587119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Oral Budesonide, 3 mg three times daily, will be given for 1 year.
Study: NCT02874092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study: NCT04353037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 HCQ
Description: Enrolled participants randomized in Group 1 receive the HCQ drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 HCQ
Description: Enrolled participants randomized in Group 1 receive the HCQ drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 Placebo
Description: Enrolled participants randomized in Group 2 will receive a placebo drug
Study: NCT02874092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX therapy
Study: NCT01974284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: percutaneous ethanol ablation
Description: The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
Study: NCT02229357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrniFlu® inactivated vaccine
Description: All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
Study: NCT02339051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping on one leg
Study: NCT03561311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
Study: NCT04353037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 Placebo
Description: Enrolled participants randomized in Group 2 will receive a placebo drug
Study: NCT00913913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC Vaccine therapy 10E7 intranodally every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg iv every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 18 MiU/m2 CI 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN
Description: IFN 6 MiU subc TIW
Study: NCT01137799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 50mg nanosuspension (sort of liquid formulation) once daily (single dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 200mg nanosuspension (sort of liquid formulation) once daily (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 100mg nanosuspension (sort of liquid formulation) once daily (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 10mg nanosuspension (sort of liquid formulation) once daily (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
Study: NCT03710564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: 6 mg/0.05mL solution for intravitreal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg/0.05mL solution for intravitreal injection
Study: NCT00878618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
Study: NCT05679830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
Study: NCT01393353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: computer game
Study: NCT02378714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASC
Description: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASC
Description: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
Study: NCT00572078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
Study: NCT03571191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
Study: NCT02065050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: team-based care
Description: Patients in the eDMS arm are called at least every month for their diabetes treatment.
Study: NCT06239948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With Music
Description: each subject was placed in a TMS laboratory with music for 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without Music
Description: each subject was placed in a TMS laboratory without music for 20 minutes
Study: NCT00726999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Administered as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Administered as needed
Study: NCT02616861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: IW-1973 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablet
Description: Matching placebo tablet
Study: NCT00506727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (ADDERALL XR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Study: NCT02675920

Intervention type: DRUG
Intervention: non-ionic monomer iodinated CT contrast media
Description: patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
Study: NCT02624219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
Study: NCT02508896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® AT04A+adjuvant
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® AT06A+adjuvant
Description: subcutaneous injection
Study: NCT03739138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
Study: NCT03330236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthetic depth management
Description: The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
Study: NCT01194102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Based Exercise Program
Description: Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Living with Stroke Education program
Description: Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: YMCA membership
Description: Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
Study: NCT02508896

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant without active component
Description: subcutaneous injection
Study: NCT04182997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
Study: NCT01194102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YMCA membership
Description: Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
Study: NCT01419587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
Study: NCT02881086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Study: NCT03561311

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: Nelarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Nelarabine
Study: NCT03107962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 Blocking Antibody)
Description: pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
Study: NCT02546219

Intervention type: OTHER
Intervention: Eosinophil isolation and characterization.
Description: Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.